Clinical features and risk factors of creatine kinase elevations and myopathy associated with telbivudine

Journal of Viral Hepatitis

Volumn 18, Issue 12, 2011, Pages 892-896

  Zou, X J ^a   Jiang, X Q ^a   Tian, D Y ^a  

^a HUAZHONG UNIVERSITY OF SCIENCE AND TECHNOLOGY   (China)

Author keywords

creatine kinase elevation; hepatitis B virus; myopathy; myositis; rhabdomyolysis; telbivudine

Indexed keywords

CREATINE KINASE; HEPATITIS B(E) ANTIGEN; TELBIVUDINE; VIRUS DNA;

ADOLESCENT; ADULT; AGED; ARTICLE; CLINICAL FEATURE; CLINICAL TRIAL; CREATINE KINASE BLOOD LEVEL; DRUG SUBSTITUTION; DRUG WITHDRAWAL; FEMALE; GROUPS BY AGE; HEPATITIS B; HUMAN; HUMAN EXPERIMENT; INCIDENCE; MAJOR CLINICAL STUDY; MALE; MYOPATHY; MYOSITIS; PATIENT MONITORING; PREDICTION; PRIORITY JOURNAL; RHABDOMYOLYSIS; RISK FACTOR; SIDE EFFECT;

ADOLESCENT; ADULT; AGE DISTRIBUTION; AGED; ANTIVIRAL AGENTS; CREATINE KINASE; FEMALE; HEPATITIS B, CHRONIC; HUMANS; INCIDENCE; MALE; MIDDLE AGED; MUSCULAR DISEASES; NUCLEOSIDES; PYRIMIDINONES; RISK FACTORS; SEX DISTRIBUTION; YOUNG ADULT;

EID: 81555215457     PISSN: 13520504     EISSN: 13652893     Source Type: Journal    
DOI: 10.1111/j.1365-2893.2010.01412.x     Document Type: Article

References (18)

1. Liaw YF, Gane E, Leung N, et al. 2-Year GLOBE trial results: telbivudine Is superior to lamivudine in patients with chronic hepatitis B. Gastroenterology 2009; 136 (2): 486-495.
2. Ojetti V, Gasbarrini A, Migneco A, et al. Lamivudine-induced muscle mitochondrial toxicity. Dig Liver Dis 2002; 34 (5): 384-385.
3. Seok JI, Lee DK, Lee CH, et al. Long-term therapy with clevudine for chronic hepatitis B can be associated with myopathy characterized by depletion of mitochondrial DNA. Hepatology 2009; 49 (6): 2080-2086.
4. Fleischer RD, Lok AS,. Myopathy and neuropathy associated with nucleos(t)ide analog therapy for hepatitis B. J Hepatol 2009; 51 (4): 787-791.
5. Liu CY, Xie ZY, Qin L,. An unusual reaction to telbivudine: rhabdomyolysis. Yao Wu Bu Liang Fan Ying Za Zhi 2009; 11 (3): 201-202.
6. Zhang XS, Jin R, Zhang SB, Tao ML,. Clinical features of adverse reactions associated with telbivudine. World J Gastroenterol 2008; 14 (22): 3549-3553.
7. European Association For The Study Of The Liver. EASL Clinical Practice Guidelines: management of chronic hepatitis B. J Hepatol 2009; 50 (2): 227-242.
8. Avila C, Laeufle R, Bao W,. CK elevation during chronic hepatitis B (CHB)treatment with telbivudine: experience from the combined GLOBE f NV-02B-007/CLDT600A2302) and NV-02B-015(015) study clinical safety database: Poster#PE 140. Presented at The 19th Asian Pacific Association for the Study of the Liver (APASL); 13-16 February, 2009, Hong Kong.
9. Pasternak RC, Smith Jr SC, Bairey-Merz CN, Grundy SM, Cleeman JI, Lenfant C,. ACC/AHA/NHLBI Clinical Advisory on the Use and Safety of Statins. Stroke 2002; 33 (9): 2337-2341. (Pubitemid 35014654)
10. Lai CL, Gane E, Liaw YF, et al. Telbivudine versus lamivudine in patients with chronic hepatitis B. N Engl J Med 2007; 357 (25): 2576-2588. (Pubitemid 350294224)
11. Wu S, Kanda T, Imazeki F, et al. Hepatitis B virus e antigen downregulates cytokine production in human hepatoma cell lines. Viral Immunol 2010; 23 (5): 467-476.
12. Kramer HF, Goodyear LJ,. Exercise, MAPK, and NF-kappaB signaling in skeletal muscle. J Appl Physiol 2007; 103 (1): 388-395. (Pubitemid 47092316)
13. Brown CA, Smith F, Laessig KA,. Creatine kinase elevations and muscle toxicities associated with chronic telbivudine use in prospective clinical trials. Hepatology 2007; 46 (Suppl 1): 655.
14. Matthews SJ,. Telbivudine for the management of chronic hepatitis B virus infection. Clin Ther 2007; 29 (12): 2635-2653.
15. Bishop JB, Tani Y, Witt K, et al. Mitochondrial damage revealed by morphometric and semiquantitative analysis of mouse pup cardiomyocytes following in utero and postnatal exposure to zidovudine and lamivudine. Toxicol Sci 2004; 81 (2): 512-517. (Pubitemid 39377980)
16. Kim JW, Park SH, Louie SG,. Telbivudine: a novel nucleoside analog for chronic hepatitis B. Ann Pharmacother 2006; 40 (3): 472-478.
17. Rosenfeldt FL, Mijch A, McCrystal G, et al. Skeletal myopathy associated with nucleoside reverse transcriptase inhibitor therapy: potential benefit of coenzyme Q10 therapy. Int J STD AIDS 2005; 16 (12): 827-829. (Pubitemid 43116707)
18. Wyman M, Leonard M, Morledge T,. Coenzyme Q10: a therapy for hypertension and statin-induced myalgia. Cleve Clin J Med 2010; 77 (7): 435-442.